2014-05-012024-05-18https://scholars.lib.ntu.edu.tw/handle/123456789/701948隨著現代醫療水準大幅提昇，急性腎損傷患者的發生率仍居高不下，危急患者合併 急性腎損傷之死亡率高達百分之60〜70%，造成處理伴隨急性腎損傷的合併症付出之醫 療成本相對龐大。台灣急性腎損傷及腎病臨床試驗合作聯盟（CAKs)由多位腎病和重症 醫學的專家所組成，在急性腎損傷和重症醫學的領域有豐富的基礎研究、臨床實務以及 產學合作經驗，提供國内外廠商珍貴的急性腎損傷臨床諮詢，而業界開發之新式藥物以 及檢驗方法可在本平台下獲得最大效益之驗證。 CAKs成立的主要任務是；（1)整合國内各醫學中心及醫院的醫療資源，協助國内外 產業及藥廠進行腎臟相關疾病之臨床試驗。（2)建置跨院際急性腎損傷患者的資料庫。 中心辦公室提供通訊聯絡、資料庫維護和核心研究的協調窗口 ；核心設施提供臨床研究 者執行標準化的新式生物指標分析，檢測患者包括血液/尿液/腎切片檢體。台灣急性腎 損傷及腎病臨床試驗合作聯盟具備每年招收至少500例急性腎損傷病患者的能力，利 用網路建置系統收集全國性急性透析病人的臨床資料提供分析。我們本年度以（1)奈米 活性碳吸附治療急性腎損傷。（2)細胞激素吸附治療敗血性腎衰竭。（3)臨床檢體驗證台 大電機系聯發科合作開發的急性腎損傷晶片。 CAKs的目標是推動有治療潛力的急性腎損傷臨床試驗，加速治療方法發展，降低急 性腎損傷的發生率，減緩併發慢性腎病、末期腎病的機率，務求協助國人延長壽命、追 求良好的生活品質。The incidence rate of acute kidney injury (AKI) in hospitalized patients is increasing, and the number of deaths associated with dialysis-requiring AKI has more than doubled. In hospitalized patients, AKI results in increased in-hospital and post-hospitalization resource utilization. Currently, the incidence rate of dialysis-requiring AKI is higher than that of end-stage renal disease (ESRD), and its annual growth rate is as high as 10% in the United States. To promote Taiwan Consortium of Acute Kidney Injury and Renal Diseases (CAKs) as the leading kidney diseases of clinical trial group in Asia-Pacific by establishing a cohesive group of kidney clinical trial sites that conduct uniform standard-of-care and high quality clinical trial performance in renal diseases and provide credible and reliable data. The participating investigators of CAKs are specialists of kidney medicine who have experience in conducting bench and clinical studies of AKI. The key missions of the CAKs will be to assist the design and conduct of multi-center investigator-initiated, industry or international research groups) clinical trials, as well as the establishment of biospecimen database of AKI patients. Central office will provide the window of communication, database auditing and the improving quality of specimens, and core study coordination. The core facility of CAKs will provide Standardized analysis for novel AKI biomarkers. Participating subjects need to sign the informed consent for clinical data , PBMC/plasma/serum/ specimens from kidney biopsy. This year , we will work on 1. Improved AKI using “adsorbent，，Clinical prospective multicenter randomized controlled trial (RCT) study.2. The Effect of Endotoxin Adsorbed Hemoperfusion on the Microcirculation in Patients with Severe Sepsis and Septic Shock. 3. Validation the device from Advanced Circuits Research Laboratory By estimation, the consortium has the ability to enroll AKI patients and record the acute dialysis during intensive units. Core clinical information will be collected using a web based information system for future analysis. The ultimate goal for CAKs is to enable clinical trials of potential therapies for AKI and speed the development of treatments that will improve the severity of end stage renal disease and mortality for patients with AKI.急性腎損傷臨床試驗奈米活性碳晶片